DOI: Published online: July 24, 2025 1 Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Correspondence to Seok-Woo Hong, PhD Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Email: [email protected] Won-Young Lee, MD Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Email: [email protected] *Jinmi Lee and Eun-Jung Rhee contributed equally to this work as co-first authors
One of the most promising new options is tirzepatide a medication recently approved not only for type 2 diabetes but also for chronic weight management
Mochi intends to evaluate the final prescribing information and offer the medication once FDA approval is granted
Y1-R and Y2-R agonism to stimulate G i proteins and to inhibit adenylyl cyclase was monitored by detecting the ability of PYY peptides, GEP44, or GEP12 to counteract the ability of Adenosine (acting through endogenous A2B receptor and Gs proteins) to increase levels of cAMP
Millions are using them
